.

Deeper Knowledge, Faster

  • Identify first generic entrants
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

US Army
Argus Health
McKesson
Cerilliant
Fish and Richardson
Deloitte
Cantor Fitzgerald
Medtronic
Novartis
Teva

Generated: December 14, 2017

DrugPatentWatch Database Preview

Takeda Company Profile

« Back to Dashboard

What is the competitive landscape for TAKEDA, and when can generic versions of TAKEDA drugs launch?

TAKEDA has twenty-one approved drugs.

There are eighty-three US patents protecting TAKEDA drugs and there have been two Paragraph IV challenges on TAKEDA drugs in the past three years.

There are one thousand and sixty-nine patent family members on TAKEDA drugs in fifty-nine countries and one hundred and twenty-eight supplementary protection certificates in fifteen countries.

Summary for Takeda

International Patents:1069
US Patents:83
Tradenames:22
Ingredients:16
NDAs:21
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Takeda Pharms UsaTRINTELLIXvortioxetine hydrobromideTABLET;ORAL204447-003Sep 30, 2013DISCNYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-001Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaULORICfebuxostatTABLET;ORAL021856-002Feb 13, 2009RXYesYes► Subscribe► Subscribe► SubscribeYY► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-001Jan 30, 2009RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-002Jan 25, 2013RXYesNo► Subscribe► Subscribe► SubscribeY► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-004Jan 25, 2013RXYesNo► Subscribe► Subscribe► Subscribe► Subscribe
Takeda Pharms UsaDEXILANT SOLUTABdexlansoprazoleTABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL208056-001Jan 26, 2016DISCNYesNo► Subscribe► Subscribe► SubscribeYY► Subscribe
Takeda Pharms UsaCOLCRYScolchicineTABLET;ORAL022352-001Jul 29, 2009RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Takeda

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-002Jul 15, 1999► Subscribe► Subscribe
Takeda Pharms NaPREVACIDlansoprazoleFOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001► Subscribe► Subscribe
Takeda Pharms NaPREVACIDlansoprazoleFOR SUSPENSION, DELAYED RELEASE;ORAL021281-002May 3, 2001► Subscribe► Subscribe
Takeda Pharms UsaACTOSpioglitazone hydrochlorideTABLET;ORAL021073-001Jul 15, 1999► Subscribe► Subscribe
Takeda Pharms UsaKAZANOalogliptin benzoate; metformin hydrochlorideTABLET;ORAL203414-002Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaPREVACIDlansoprazoleTABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL021428-001Aug 30, 2002► Subscribe► Subscribe
Takeda Pharms NaPREVACIDlansoprazoleFOR SUSPENSION, DELAYED RELEASE;ORAL021281-001May 3, 2001► Subscribe► Subscribe
Takeda Pharms UsaOSENIalogliptin benzoate; pioglitazone hydrochlorideTABLET;ORAL022426-005Jan 25, 2013► Subscribe► Subscribe
Takeda Pharms UsaDEXILANTdexlansoprazoleCAPSULE, DELAYED RELEASE;ORAL022287-002Jan 30, 2009► Subscribe► Subscribe
Takeda Pharms NaPREVACID IVlansoprazoleINJECTABLE;INTRAVENOUS021566-001May 27, 2004► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for TAKEDA drugs

Drugname Dosage Strength Tradename Submissiondate
alogliptinTablets6.25 mg, 12.5 mg and 25 mgNESINA1/25/2017
alogliptin and metformin hydrochlorideTablets12.5 mg/500 mg and 12.5 mg/1000 mgKAZANO1/25/2017
febuxostatTablets40 mg and 80 mgULORIC2/13/2013
colchicineTablets0.6 mgCOLCRYS12/23/2011
pioglitazone hydrochloride and metformin hydrochlorideExtended-release Tablets15 mg/1000 mg and 30 mg/1000 mgACTOPLUS MET XR9/23/2011
dexlansoprazoleDelayed-release Capsule30 mgDEXILANT11/30/2010
dexlansoprazoleCapsule60 mgDEXILANT8/25/2010
pioglitazone hydrochloride and glimepirideTablets30 mg/2 mg and 30 mg/4 mgDUETACT12/22/2009
ramelteonTablets8 mgROZEREM7/22/2009
pioglitazone hydrochloride and metformin hydrochlorideTablets15 mg/500 mg and 15 mg/850 mgACTOPLUS MET3/6/2008
lansoprazoleDelayed-release Orally Disinte15 mg and 30 mgPREVACID12/27/2006
lansoprazoleDelayed-release Pellets/Capsul15 mg and 30 mgPREVACID12/5/2005

Non-Orange Book Patents for Takeda

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,211,206 Pharmaceutical composition► Subscribe
6,174,904 Pharmaceutical composition► Subscribe
6,121,295 Pharmaceutical composition► Subscribe
6,214,848 Pharmaceutical composition► Subscribe
8,664,2251-[2-(2,4-dimethylphenylsulfanyl)-phenyl] piperazine as a compound with combined serotonin reuptake, 5-HT3 and 5-HT1A activity for the treatment of pain or residual symptoms in depression relating to sleep and cognition► Subscribe
8,309,125Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative► Subscribe
7,148,238Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
9,708,280Phenyl-piperazine derivatives as serotonin reuptake inhibitors► Subscribe
6,599,923 Pharmaceutical composition► Subscribe
6,911,459 Pharmaceutical composition► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Takeda Drugs

Country Document Number Estimated Expiration
World Intellectual Property Organization (WIPO)03015775► Subscribe
Germany69637988► Subscribe
BrazilPI0414471► Subscribe
Germany602004015067► Subscribe
Spain2505665► Subscribe
Eurasian Patent Organization200702656► Subscribe
Taiwan200302742► Subscribe
South Korea20090125251► Subscribe
World Intellectual Property Organization (WIPO)2008100240► Subscribe
South Korea20060118020► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Takeda Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB10/011United Kingdom► SubscribePRODUCT NAME: THE COMBINATION OF PIOGLITAZONE OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, ESPECIALLY THE HYDROCHLORIDE SALT, AND GLIMEPIRIDE.; REGISTERED: UK EU/1/06/366/001 20070108; UK EU/1/06/366/002 20070108; UK EU/1/06/366/003 20070108; UK EU/1/06/366/004 20070108; UK EU/1/06/366/005 20070108; UK EU/1/06/366/006 20070108; UK EU/1/06/366/019 20070108; UK EU/1/06/366/020 20070108; UK EU/1/06/366/021 20070108; UK EU/1/06/366/022 20070108; UK EU/1/06/366/013 20070108; UK EU/1/06/366/014 20070108; UK EU/1/06/366/015 20070108; UK EU/1/06/366/016 20070108; UK EU/1/06/366/017 20070108; UK EU/1/06/366/018 20070108; UK EU/1/06/366/007 20070108; UK EU/1/06/366/008 20070108; UK EU
1084705/04Switzerland► SubscribePRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 61893 08.03.2012
1084705/02Switzerland► SubscribePRODUCT NAME: VILDAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 57834 30.04.2008
0308Netherlands► Subscribe300308, 20170424, EXPIRES: 20220423
01C/011Belgium► SubscribePRODUCT NUMBER: PIOGLITAZONE; NAT. REGISTRATION NO/DATE: EU/1/001/150/001 20001018; FIRST REGISTRATION NO: CH 55378 01 20000927
2010005Lithuania► SubscribePRODUCT NAME: FEBUXOSTATUM; REGISTRATION NO/DATE: EU/1/08/447/001-EU/1/08/447/004 20080421
1084705/01Switzerland► SubscribePRODUCT NAME: SITAGLIPTIN; REGISTRATION NO/DATE: SWISSMEDIC 57863 18.04.2007
77; 5006-2008Slovakia► SubscribePRODUCT NAME: SITAGLIPTIN A METFORMIN; REGISTRATION NO/DATE: EU/1/08/455/001-014 20080716
00708Netherlands► SubscribePRODUCT NAME: LINAGLIPTIN; REGISTRATION NO/DATE: EU/1/11/707/001-011 20111224
C0033France► SubscribePRODUCT NAME: VORTIOXETINE OU L'UN DE SES SELS D'ADDITION D'ACIDE PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE: EU/1/13/891 20131218
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Johnson and Johnson
Chinese Patent Office
QuintilesIMS
Harvard Business School
UBS
Argus Health
Farmers Insurance
Teva
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot